CAJ | 학술논문

目的分析miR-224在弥漫大B细胞淋巴瘤(DLBCL)患者中的表达及其与临床病理特征和预后的关系.方法以168例DLBCL患者为研究对象,以25份无肿瘤细胞侵犯的正常淋巴结组织标本为对照,采用Real-time PCR技术检测其miR-224的相对表达水平,并探讨miR-224表达水平与患者临床病理特征及预后的关系.结果 DLBCL患者淋巴结组织中miR-224表达水平为0.97±0.33,对照组为1.87±0.43,两者比较差异有统计学意义(P＜0.05).miR-224在DLBCL患者中的表达与患者年龄(P=0.434)、性别(P=0.613)、疾病分期(P=0.250)、国际预后指数(P=0.355)、LDH(P=0.398)均无相关性.以DLBCL患者miR-224表达水平的平均值为阈值,将患者分为高表达组和低表达组,两组患者的5年无进展生存率及总生存率差异均有统计学意义(P值均＜0.05),前者均较后者高.结论 miR-224可能作为抑癌基因干扰DLBCL的发生、发展,其表达水平可作为DLBCL患者预后判断的标志.
목적 분석miR-224재미만대B세포림파류(DLBCL)환자중적표체급기여림상병리특정화예후적관계.방법 이168례DLBCL환자위연구대상,이25빈무종류세포침범적정상림파결조직표본위대조,채용Real-time PCR기술검측기miR-224적상대표체수평,병탐토miR-224표체수평여환자림상병리특정급예후적관계.결과 DLBCL환자림파결조직중miR-224표체수평위0.97±0.33,대조조위1.87±0.43,량자비교차이유통계학의의(P＜0.05).miR-224재DLBCL환자중적표체여환자년령(P=0.434)、성별(P=0.613)、질병분기(P=0.250)、국제예후지수(P=0.355)、LDH(P=0.398)균무상관성.이DLBCL환자miR-224표체수평적평균치위역치,장환자분위고표체조화저표체조,량조환자적5년무진전생존솔급총생존솔차이균유통계학의의(P치균＜0.05),전자균교후자고.결론 miR-224가능작위억암기인간우DLBCL적발생、발전,기표체수평가작위DLBCL환자예후판단적표지.
Objective To investigate the expression ofmiR-224 in diffuse large B cell lymphoma (DLBCL) and its relationship with clinical pathological features and prognosis.Methods Real-time PCR was used to detect the expression of miR-224 in 168 DLBCL and 25 normal lymphoid tissues.Results The expression of miR-224 in DLBCL (0.97±0.33) was significantly lower than that in normal lymphoid tissues (1.87±0.43,P＜0.05).There were no significant correlations between the miR-224 expression and age (P=0.434),gender (P=0.613) tumors stage (P=0.250),IPI (P=0.355) and lactate dehydrogenase (P=0.398).Using the median of miRNA-224 expression as threshold,we subdivided patients into low and high expression group.The five-year progression-free survival and overall survival were significantly lower in low expression group as compared to those in high expression group.Conclusions miR-224 expression may play an important role in the development and progression of DLBCL and could be prognostic significance.